AGIO

Agios Pharmaceuticals

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

04/29/26

Business Summary

AGIO is a clinical-stage biotechnology company that develops targeted therapies, generating cash primarily through product commercialization, licensing arrangements, and strategic collaborations rather than diversified operating cash flow. Its moat is intellectual property-driven: proprietary compounds, regulatory exclusivity, and specialized metabolic pathway expertise create barriers that are scientific rather than scale-based. Success hinges on converting R&D spending into approved therapies that command premium pricing in niche patient populations. The durability of its model depends on continuously replenishing its pipeline while managing burn, making capital allocation discipline as important as scientific innovation.

VALUATION

P/E

-

Market Cap ($M USD)

$1,928

Forward P/E

-

PEG

-

PRICE TO SALES

35.3

PRICE TO BOOK

1.6

EV / EBITDA

-2.4

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$7.12

Next Year EPS Growth Estimate

-$5.14

Next Year Revenue Growth Estimate

162.00%

Return on Equity (ROE)

-34.60%

Operating Margin

-873.90%

Debt-to-Equity

0

Piotroski F-Score

5

Altman Z-Score

10.1

Return on Invested Capital (ROIC)

-33.10%%

Current Ratio

11.5

Quick Ratio

Gainseekers Quantitative Analysis

Summary

This is a pure high-risk biotech balance sheet story masquerading as a $1,928M equity. With no P/E, no Forward P/E, and a PEG of “-”, the market has zero earnings visibility and is pricing the company entirely on pipeline optionality rather than fundamentals. Operating Margin of -34.60%, ROIC of -33.10%, and EPS of -2.4 (with EPS Next Year estimated at -$7.12) confirm deepening losses, yet the Altman Z-Score of 10.1 signals extremely low bankruptcy risk and a fortress-like solvency profile despite the noise created by a Debt/Equity of -873.90%. This is not statistically cheap at 35.3x sales, but the 1.6 Price/Book combined with a 11.5 Current Ratio implies balance sheet strength that gives management time—this is a liquidity-rich, earnings-poor biotech that the market is valuing on long-duration scientific optionality rather than cash flow.

AI Exposure / Tech Reliance

As a Biotechnology company, AGIO operates in a sector that is increasingly leveraging AI for drug discovery, trial optimization, and molecular targeting. While no direct AI metrics are provided, companies in this industry that effectively integrate computational biology can accelerate pipelines and reduce burn rates. The ability to modernize R&D workflows will be critical given its current negative margins and projected EPS decline.

The Bull Case

A deep value or GARP investor looking at this name is not buying earnings—they are buying durability and balance sheet resilience. The Altman Z-Score of 10.1 and Current Ratio of 11.5 are extraordinary, signaling substantial liquidity and minimal near-term financial distress risk, which is rare for a company running Operating Margins of -34.60%. Despite ROIC at -33.10% and a Piotroski F-Score of 5 (neutral, not distressed), the 1.6 Price/Book suggests the market is not placing an excessive premium on net assets relative to many biotech peers. Institutional Ownership at $43.75 indicates meaningful professional participation, reinforcing that sophisticated investors see embedded pipeline value that outweighs present losses. This is a classic asymmetric setup: strong solvency metrics supporting a speculative R&D engine.

The Bear Case

The bear case is brutal. A Price/Sales ratio of 35.3 with Sales Growth Next Year projected at -$5.14 is a valuation-growth mismatch bordering on speculative excess. EPS is -2.4 and expected to deteriorate to -$7.12, while ROIC of -33.10% and Operating Margin of -34.60% confirm that capital is currently being destroyed, not compounded. The Debt/Equity ratio of -873.90% signals a severely distorted capital structure—likely negative equity dynamics—which can amplify volatility and undermine long-term capital efficiency. With no earnings, no yield, and no defined PEG or Forward P/E, investors are exposed to binary clinical and regulatory risk without traditional valuation anchors.

Market Sentiment & Smart Money

Short Interest %

10.60%

Analyst Consensus

1.73

Average Analyst Price Target

$43.75

Institutional Ownership %

106.30%

1-Year Beta

1.09

Insider Buying % (6 Mo)

1.10%%

Distance to 52-Week High

71.60%%

Distance to 52-Week Low

148.00%%